



# Defluorosilylation of trifluoromethane: upgrading an environmentally damaging fluorocarbon†

Daniel J. Sheldon,  Greg Coates and Mark R. Crimmin \*

Cite this: *Chem. Commun.*, 2020, 56, 12929

Received 16th August 2020,  
Accepted 17th September 2020

DOI: 10.1039/d0cc04592f

rsc.li/chemcomm

**The rapid, room-temperature defluorosilylation of trifluoromethane, a highly potent greenhouse gas, has been achieved using a simple silyl lithium reagent. An extensive computational mechanistic analysis provides a viable reaction pathway and demonstrates the unexpected electrophilic nature of LiCF<sub>3</sub>. The reaction generates a bench stable fluorinated building block that shows promise as an easy-to-use difluoromethylating agent. The difluoromethyl group is an increasingly important bioisostere in active pharmaceutical ingredients, and therefore our methodology creates value from waste. The potential scalability of the process has been demonstrated by achieving the reaction on a gram-scale.**

Despite being widely employed as refrigerants, hydrofluorocarbons (HFCs) are potent greenhouse gases and important contributors to global warming.<sup>1,2</sup> The threat posed by HFCs was highlighted by a recent amendment to the Montreal Protocol seeking to reduce HFCs by > 80% by 2050.<sup>3</sup> Trifluoromethane (HCF<sub>3</sub>, HFC-23) has a global warming potential 11 700 times greater than CO<sub>2</sub>, and an atmospheric lifetime of 264 years.<sup>4</sup> It is produced on a vast scale (*ca.* 20 kilotons per year) as a by-product from a range of industrial processes, such as the manufacture of PTFE (Teflon) and refrigerant gases (*e.g.* ClCF<sub>2</sub>H).<sup>2,5</sup> Despite its widespread production, there is currently little application for trifluoromethane. Consequently, it is either stored or destroyed at high cost to prevent its release into the environment.<sup>2,4</sup>

In the pharmaceutical industry, fluorine substitution is commonly used to improve drug efficiency and quality by enhancing the metabolic stability and overall bioavailability of a drug.<sup>6,7</sup> There is a particular growing interest in the use of the difluoromethyl (CF<sub>2</sub>H) group in drug design, where it is considered a lipophilic bioisostere of the hydroxyl, thiol and amine groups.<sup>8,9</sup> The CF<sub>2</sub>H moiety is already present in various

commercialised pharmaceuticals such as Eflornithine and Pantoprazole (Fig. 1b).<sup>10,11</sup> The growth in interest for CF<sub>2</sub>H installation has created a growing demand for an easy-to-use, mild difluoromethylating agent.<sup>12,13</sup>

We postulated the potential environmental and economic benefit in the use of trifluoromethane as a feedstock gas for the synthesis of a valuable difluoromethyl building block, by developing a process to transform the C–F bond into a reactive C–Si bond.

Much progress has been made in the field of upgrading fluorocarbons into reactive building blocks, particularly with the use of nucleophilic main group reagents.<sup>1,14,15</sup> Fluoroalkanes remain the least reactive substrates due to high sp<sup>3</sup> C–F bond dissociation energies and a lack of charge stabilisation in the bond-breaking transition state.<sup>1,16</sup> Despite this, our group has in recent years demonstrated the C–F activation of simple fluoroalkanes using aluminium and magnesium nucleophiles.<sup>17,18</sup> Furthermore, the groups of Shibata and Martin have both reported C–F activation of a range of fluoroalkanes using group 1 metal silyl nucleophiles.<sup>19,20</sup> We also recently reported the defluorosilylation of industrially relevant hydrofluoroolefins (HFOs) with simple silyl lithium reagents,<sup>21</sup> and in this work we sought to extend the methodology to HFCs.

Trifluoromethane itself has very limited synthetic use, stemming from its low boiling point (–83 °C) and its relatively acidic C–H bond (p*K*<sub>A</sub> ~ 25 in H<sub>2</sub>O).<sup>2</sup> The CF<sub>3</sub><sup>–</sup> anion generated




Fig. 1 (a) Umpolung reactivity mode of HCF<sub>3</sub>. (b) Pharmaceuticals containing the CF<sub>2</sub>H moiety.

Molecular Sciences Research Hub, Department of Chemistry, Imperial College London, London W12 0BZ, UK. E-mail: m.crimmin@imperial.ac.uk

† Electronic supplementary information (ESI) available: Experimental and computational details. See DOI: 10.1039/d0cc04592f






Fig. 2 Reaction scheme for the defluorosilylation of trifluoromethane.

from deprotonation can decompose into difluorocarbene ( $:\text{CF}_2$ ) and a fluoride anion ( $\text{F}^-$ ),<sup>2,5,22,23</sup> although under appropriate conditions it has been utilised in trifluoromethylation reactions (Fig. 1a).<sup>2,24</sup> However, there are only a handful of examples where trifluoromethane is employed as a  $\{\text{CF}_2\text{H}\}^+$  synthon through C–F functionalisation.<sup>25–30</sup> Mikami and co-workers used a highly nucleophilic boryl lithium reagent to demonstrate the defluoroborylation of  $\text{HCF}_3$  to form an organoboron building block.<sup>28</sup> While a mechanistic study was not carried out for this system, a related computational study by Mikami on the  $\alpha$ -difluoromethylation of lithium enolates was utilised to propose a pathway for the defluoroborylation.<sup>26</sup> The authors suggest initial deprotonation of  $\text{HCF}_3$  occurs to form  $\text{LiCF}_3$ , before C–F cleavage then proceeds *via* an  $\text{S}_{\text{N}}2$ -type attack by the nucleophilic boryl lithium at  $\text{LiCF}_3$ , in a bimetallic transition state.<sup>26</sup> While an important discovery, any application of the defluoroborylation methodology is limited by issues regarding scalability. The boryl lithium reagent is extremely difficult to synthesise and is highly susceptible to degradation, in fact it could only be synthesised *in situ* and required a temperature of  $-78^\circ\text{C}$ . The organoboron building block was reported as bench stable but its utility is unknown.<sup>28</sup>

In this paper, we report the rapid, room-temperature defluorosilylation of trifluoromethane using a simple silyl lithium reagent to form a promising difluoromethyl organosilicon building

block. This methodology offers the potential to recycle a highly abundant, low-value fluorocarbon, minimising waste and environmental damage, to create a pharmaceutically relevant building block of high-value.<sup>1</sup>

Trifluoromethane (1 bar,  $22^\circ\text{C}$ ) was added to a  $\text{C}_6\text{D}_6$  solution of the silyl lithium reagent  $\text{PhMe}_2\text{SiLi}\cdot\text{PMDETA}$  (**1-PMDETA**) (PMDETA = pentamethyldiethylenetriamine), and the building block  $\text{PhMe}_2\text{SiCF}_2\text{H}$  (**2**) was formed in a 90% spectroscopic yield (Fig. 2).  $\text{PhMe}_2\text{SiH}$  was also formed as a by-product in a 10% yield. The optimum concentration of **1-PMDETA** was found to be 0.02 M, which results in approximately 7.5 equivalents of  $\text{HCF}_3$  being added to the headspace of the reaction vessel. The yield of **2** was found to decrease with an increasing concentration of **1-PMDETA** (and a consequently decreasing equivalents of  $\text{HCF}_3$ ). It was also found that the PMDETA ligand was crucial to the reaction, with alternative THF (**1-THF**) and TMEDA (**1-TMEDA**) (TMEDA = tetramethylethylenediamine) adducts resulting in no formation of the desired product **2**. The structures of the silyl lithium nucleophiles **1-PMDETA** and **1-TMEDA** have previously been reported.<sup>21,31</sup> A solvent screen showed that polar solvents such as THF were detrimental to the yield of **2**, whilst low reaction temperatures ( $-78^\circ\text{C}$ ) altered the reaction pathway to form undesired products (see ESI,† for full details of reaction optimisation).

After achieving the defluorosilylation of  $\text{HCF}_3$  in a >90% yield on an NMR scale, we sought to demonstrate the potential scalability of this methodology, and were able to achieve the transformation on a gram-scale of **1-PMDETA**. The product  $\text{PhMe}_2\text{SiCF}_2\text{H}$  (**2**) was successfully isolated after work-up in a 68% yield.

In order to probe the mechanism, we set out to complete a kinetic analysis of the reaction by NMR spectroscopy. Unfortunately, we were unable to achieve this at room temperature as the reaction goes to completion within 5 minutes (as shown by  $^1\text{H NMR}$  spectroscopy). Efforts to obtain an analysis of the reaction at low temperature ( $-78^\circ\text{C}$ ) were thwarted by a change in reaction selectivity, where the desired product **2** was




Fig. 3 Calculated potential energy surface for trifluoromethane defluorosilylation. The B3PW91 functional was used with a hybrid basis set, 6-31g\*\*(C, H)/6-311+g\*(N, Si, Li, F). Solvation (PCM, benzene) and dispersion (GD3) were incorporated into the optimisations.






Fig. 4 Proposed reaction cycle for trifluoromethane defluorosilylation.

produced in only an 8% yield, with  $\text{PhMe}_2\text{SiH}$  and  $\text{H}_2\text{CF}_2$  instead formed as the major products (see ESI,† for full details).

An extensive DFT study was carried out to explore the mechanism (Fig. 3). Our calculations support a mechanism similar to that proposed by Mikami and co-workers for the defluoroborylation of trifluoromethane.<sup>26,28</sup> The first step is deprotonation of  $\text{HCF}_3$  by **1-PMDETA**, proceeding via **TS1** ( $\Delta G_1^\ddagger = 20.5 \text{ kcal mol}^{-1}$ ) to form  $\text{PMDETA-LiCF}_3$  and the experimentally observed by-product  $\text{PhMe}_2\text{SiH}$ . The rate-determining C-F activation step then occurs by an  $\text{S}_{\text{N}}2$ -like attack by a further equivalent of **1-PMDETA** at the  $\text{PMDETA-LiCF}_3$  carbenoid, proceeding via **TS2** ( $\Delta G_2^\ddagger = 23.4 \text{ kcal mol}^{-1}$ ). In this transition state, one lithium cation stabilises the fluoride leaving group, and the other stabilises the carbenoid carbon, acting as an anchor for C-Si bond formation. It has been suggested that strong  $\text{Li} \cdots \text{F}$  interactions are crucial for stabilising similar transition states.<sup>25,26</sup> **TS2** is a concerted, albeit highly asynchronous transition state involving early C-F cleavage with concomitant LiF formation, and late C-Si

bond formation. Finally,  $\text{PhMe}_2\text{SiCF}_2\text{Li-PMDETA}$  undergoes protonation by a further equivalent of  $\text{HCF}_3$  to give the desired product **2** and  $\text{PMDETA-LiCF}_3$ , via **TS3** ( $\Delta G_3^\ddagger = 18.7 \text{ kcal mol}^{-1}$ ). The reaction is therefore proposed to be catalytic in  $\text{LiCF}_3$  (Fig. 4). All three steps are exergonic processes.

NBO analysis was carried out to elucidate the nature of the transition states (see ESI,† for full details). The NPA charge on the carbenoid carbon of  $\text{PMDETA-LiCF}_3$  in **INT3** (and subsequently **INT4** and **TS2**) was found to be positive, despite this species being viewed as carbanion (Fig. 5). This is due to the strong electron withdrawing effect of the three fluorine atoms, and has been noted in previous calculations on  $\text{LiCF}_3$ .<sup>32</sup> The positive NPA charge explains the electrophilic nature of  $\text{PMDETA-LiCF}_3$  and hence why it is attacked by the silicon nucleophile. Notably, the positive NPA charge on the carbenoid carbon increases from **INT4** (+0.55) to **TS2** (+0.64), suggesting an accumulation of positive charge approaching the transition state. This is consistent with the asynchronous nature of **TS2** where C-F cleavage occurs prior to C-Si formation. Second-order perturbation analysis of **TS2** suggests there is a small donation of electron density from a Si lone pair to a p orbital of the carbenoid carbon ( $\approx 6 \text{ kcal mol}^{-1}$ ). We therefore suggest that **TS2** possesses some  $\text{S}_{\text{N}}1$ -like character, however, is overall considered a highly asynchronous  $\text{S}_{\text{N}}2$ -like step as it is concerted in C-F cleavage and C-Si formation. The geometry of **TS2** is somewhat similar to the transition-state proposed by Mikami for the attack of a THF-stabilised lithium enolate on  $\text{LiCF}_3$ .<sup>26</sup>

Alternative mechanisms were explored by DFT calculations and ruled out on the basis of identifying transition states that were prohibitively high in energy. A classical, direct  $\text{S}_{\text{N}}2$  attack by **1-PMDETA** at  $\text{HCF}_3$  was calculated to proceed via **TS4** (see ESI†) ( $\Delta G_4^\ddagger = 53.8 \text{ kcal mol}^{-1}$ ). A ‘frontside  $\text{S}_{\text{N}}2$ ’ approach was also considered, as this mechanism has been proposed to




Fig. 5 Calculated structures for the stationary points of the C-F activation step, annotated with relevant NPA charges and Wiberg Bond Indices for C-F cleavage and C-Si formation.



operate with highly fluorophilic nucleophiles,<sup>18,33</sup> and the high-energy TS5 (see ESI†) ( $\Delta G_5^\ddagger = 44.7 \text{ kcal mol}^{-1}$ ) was found. We were unable to find a transition state for difluorocarbene formation from PMDETA-LiCF<sub>3</sub>.

The experimental observation of PhMe<sub>2</sub>SiH as a reaction by-product is consistent with deprotonation of HCF<sub>3</sub> as the first step of the reaction to form LiCF<sub>3</sub>. It has been reported that LiCF<sub>3</sub> can decompose to form LiF and :CF<sub>2</sub>.<sup>2,29,30</sup> There was no evidence for the presence of difluorocarbene (:CF<sub>2</sub>) from several carbene trapping experiments that were carried out (see ESI† for full experimental details). While these results cannot rule out a carbene mechanism entirely, they strongly suggest, in combination with results from DFT, that a carbene pathway is not occurring.

The difluoromethyl building block **2** has already been applied as an easy-to-use reagent for the installation of the CF<sub>2</sub>H moiety in carbonyl substrates.<sup>34,35</sup> Its use is somewhat scarce, however, and this could be due to the difficulty or cost of its synthesis (it requires the now-banned substance HCF<sub>2</sub>Cl).<sup>36,37</sup> Our methodology provides a simple, gram-scale synthesis of this promising difluoromethylating agent, which we believe could lead to an increase in the use of the difluoromethyl group in new pharmaceutical and agrochemical products.

In conclusion, we have developed a simple process to achieve the rapid, room-temperature defluorosilylation of an environmentally damaging fluorocarbon, trifluoromethane. The reaction generates a bench stable fluorinated building block without the need for cryogenics, in a reaction that can be performed on a gram-scale. The fluorinated building block is an established difluoromethylating agent, hence the approach allows the generation of value from waste. Through an extensive computational study, we have proposed a viable mechanism for sp<sup>3</sup> C–F bond activation, rationalising the unexpected electrophilic nature of LiCF<sub>3</sub>. The benefits of using trifluoromethane as a feedstock gas would be greatly amplified if scaled up to a continuous flow process,<sup>38</sup> and is the subject of future work in our laboratories.

We are grateful to Dr David Mills and co-workers. The ERC is thanked for generous funding (StG: 677367).

## Conflicts of interest

There are no conflicts to declare.

## Notes and references

- 1 G. Coates, F. Rekhroukh and M. R. Crimmin, *Synlett*, 2019, 2233–2246.
- 2 G. K. S. Prakash, P. V. Jog, P. T. D. Batamack and G. A. Olah, *Science*, 2012, **338**, 1324–1327.
- 3 EU ratifies Kigali Amendment to the Montreal Protocol | Climate Action [https://ec.europa.eu/clima/news/eu-ratifies-kigali-amendment-montreal-protocol\\_en](https://ec.europa.eu/clima/news/eu-ratifies-kigali-amendment-montreal-protocol_en).
- 4 W. Han, Y. Li, H. Tang and H. Liu, *J. Fluorine Chem.*, 2012, **140**, 7–16.
- 5 S. Kyasa, *Synlett*, 2015, 1911–1912.
- 6 S. Purser, P. R. Moore, S. Swallow and V. Gouverneur, *Chem. Soc. Rev.*, 2008, **37**, 320–330.
- 7 M. Inoue, Y. Sumii and N. Shibata, *ACS Omega*, 2020, **5**, 10633–10640.
- 8 Y. Zafrani, D. Yeffet, G. Sod-Moriah, A. Berliner, D. Amir, D. Marciano, E. Gershonov and S. Saphier, *J. Med. Chem.*, 2017, **60**, 797–804.
- 9 G. K. S. Prakash, S. Krishnamoorthy, S. K. Ganesh, A. Kulkarni, R. Haiges and G. A. Olah, *Org. Lett.*, 2014, **16**, 54–57.
- 10 R. A. Casero and P. M. Woster, *J. Med. Chem.*, 2009, **52**, 4551–4573.
- 11 S. M. Cheer, A. Prakash, D. Faulds and H. M. Lamb, *Drugs*, 2003, **63**, 101–133.
- 12 D. E. Yerien, S. Barata-Vallejo and A. Postigo, *Chem. – Eur. J.*, 2017, **23**, 14676–14701.
- 13 S. Monfette, Y.-Q. Fang, M. M. Bio, A. R. Brown, I. T. Crouch, J.-N. Desrosiers, S. Duan, J. M. Hawkins, C. M. Hayward, N. Peperni and J. P. Rainville, *Org. Process Res. Dev.*, 2020, **24**, 1077–1083.
- 14 T. Ahrens, J. Kohlmann, M. Ahrens and T. Braun, *Chem. Rev.*, 2015, **115**, 931–972.
- 15 W. Chen, C. Bakewell and M. Crimmin, *Synthesis*, 2016, 810–821.
- 16 S. J. Blanksby and G. B. Ellison, *Acc. Chem. Res.*, 2003, **36**, 255–263.
- 17 M. R. Crimmin, M. J. Butler and A. J. P. White, *Chem. Commun.*, 2015, **51**, 15994–15996.
- 18 G. Coates, B. J. Ward, C. Bakewell, A. J. P. White and M. R. Crimmin, *Chem. – Eur. J.*, 2018, **24**, 16282–16286.
- 19 B. Cui, S. Jia, E. Tokunaga and N. Shibata, *Nat. Commun.*, 2018, **9**, 4393.
- 20 X.-W. Liu, C. Zarate and R. Martin, *Angew. Chem., Int. Ed.*, 2019, **58**, 2064–2068.
- 21 G. Coates, H. Y. Tan, C. Kalf, A. J. P. White and M. R. Crimmin, *Angew. Chem., Int. Ed.*, 2019, **58**, 12514–12518.
- 22 C. P. Johnston, T. H. West, R. E. Dooley, M. Reid, A. B. Jones, E. J. King, A. G. Leach and G. C. Lloyd-Jones, *J. Am. Chem. Soc.*, 2018, **140**, 11112–11124.
- 23 A. García-Domínguez, T. H. West, J. J. Primožic, K. M. Grant, C. P. Johnston, G. G. Cumming, A. G. Leach and G. C. Lloyd-Jones, *J. Am. Chem. Soc.*, 2020, **142**, 14649–14663.
- 24 P. Novák, A. Lishchynskiy and V. V. Grushin, *J. Am. Chem. Soc.*, 2012, **134**, 16167–16170.
- 25 T. Iida, R. Hashimoto, K. Aikawa, S. Ito and K. Mikami, *Angew. Chem., Int. Ed.*, 2012, **51**, 9535–9538.
- 26 K. Honda, T. V. Harris, M. Hatanaka, K. Morokuma and K. Mikami, *Chem. – Eur. J.*, 2016, **22**, 8796–8800.
- 27 K. Aikawa, K. Maruyama, K. Honda and K. Mikami, *Org. Lett.*, 2015, **17**, 4882–4885.
- 28 S. Ito, N. Kato and K. Mikami, *Chem. Commun.*, 2017, **53**, 5546–5548.
- 29 S. Okusu, E. Tokunaga and N. Shibata, *Org. Lett.*, 2015, **17**, 3802–3805.
- 30 C. S. Thomason and W. R. Dolbier, *J. Org. Chem.*, 2013, **78**, 8904–8908.
- 31 C. Strohmann and C. Däschlein, *Chem. Commun.*, 2008, 2791–2793.
- 32 J. Kvičala, J. Štambaský, S. Böhm and O. Paleta, *J. Fluorine Chem.*, 2002, **113**, 147–154.
- 33 C. Strohmann, M. Bindl, V. C. Fraaß and J. Hörnig, *Angew. Chem., Int. Ed.*, 2004, **43**, 1011–1014.
- 34 T. Hagiwara and T. Fuchikami, *Synlett*, 1995, 717–718.
- 35 Y. Zhao, W. Huang, J. Zheng and J. Hu, *Org. Lett.*, 2011, **13**, 5342–5345.
- 36 T. Fuchikami and I. Ojima, *J. Organomet. Chem.*, 1981, **212**, 145–153.
- 37 G. J. M. Velders, A. R. Ravishankara, M. K. Miller, M. J. Molina, J. Alcamo, J. S. Daniel, D. W. Fahey, S. A. Montzka and S. Reimann, *Science*, 2012, **335**, 922–923.
- 38 M. Köckinger, C. A. Hone, B. Gutmann, P. Hanselmann, M. Bersier, A. Torvisco and C. O. Kappe, *Org. Process Res. Dev.*, 2018, **22**, 1553–1563.

